Category: 21169-71-1

21169-71-1, In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 21169-71-1, name is Isoxazole-5-carboxylic acid, introducing its new discovery.

2,4-DIAMINOPYRIMIDINE DERIVATIVES AS HISTAMINE H4 MODULATORS

The present invention relates to 2,4-diaminopyrimidines and pharmaceutically acceptable salts thereof, purification methods for the same, pharmaceutical compositions containing them, methods of obtaining and using them for the treatment of disease states, disorders, and conditions mediated by the histamine H4 receptor activity.

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.21169-71-1, you can also check out more blogs about21169-71-1

Reference£º
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Chemistry is the experimental and theoretical study of materials on their properties at both the macroscopic and microscopic levels.In a patent£¬Which mentioned a new discovery about 21169-71-1, molcular formula is C4H3NO3, introducing its new discovery. , 21169-71-1

SUBSTITUTED 2-(CHROMAN-6-YLOXY)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS

The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I, in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula I are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

Because enzymes can increase reaction rates by enormous factors and tend to be very specific, 21169-71-1, typically producing only a single product in quantitative yield, they are the focus of active research.you can also check out more blogs about 21169-71-1

Reference£º
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Chemistry is the science of change. But why do chemical reactions take place? Why do chemicals react with each other? The answer is in thermodynamics and kinetics.In a document type is Article, the author is Gandhi, Disha M. and a compound is mentioned, 21169-71-1, Isoxazole-5-carboxylic acid, introducing its new discovery. 21169-71-1

Characterization of Protease-Activated Receptor (PAR) ligands: Parmodulins are reversible allosteric inhibitors of PAR1-driven calcium mobilization in endothelial cells

Several classes of ligands for Protease-Activated Receptors (PARs) have shown impressive anti-inflammatory and cytoprotective activities, including PAR2 antagonists and the PAR1-targeting parmodulins. In order to support medicinal chemistry studies with hundreds of compounds and to perform detailed mode-of-action studies, it became important to develop a reliable PAR assay that is operational with endothelial cells, which mediate the cytoprotective effects of interest. We report a detailed protocol for an intracellular calcium mobilization assay with adherent endothelial cells in multiwell plates that was used to study a number of known and new PAR1 and PAR2 ligands, including an alkynylated version of the PAR1 antagonist RWJ-58259 that is suitable for the preparation of tagged or conjugate compounds. Using the cell line EA.hy926, it was necessary to perform media exchanges with automated liquid handling equipment in order to obtain optimal and reproducible antagonist concentration-response curves. The assay is also suitable for study of PAR2 ligands; a peptide antagonist reported by Fairlie was synthesized and found to inhibit PAR2 in a manner consistent with reports using epithelial cells. The assay was used to confirm that vorapaxar acts as an irreversible antagonist of PAR1 in endothelium, and parmodulin 2 (ML161) and the related parmodulin RR-90 were found to inhibit PAR1 reversibly, in a manner consistent with negative allosteric modulation.

Interested yet? Keep reading other articles of 1246765-38-7!, 21169-71-1

Reference£º
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

21169-71-1, Chemistry is traditionally divided into organic and inorganic chemistry. The former is the study of compounds containing at least one carbon-hydrogen bonds.In a patent£¬Which mentioned a new discovery about 21169-71-1

PYRAZOLE DERIVATIVES

A compound represented by the general formula (I), which is useful as a peroxisome proliferator-activated receptor E/G agonist, a salt of the compound, and a solvate of either. (In the formula, X, Y, and Z each represents nitrogen or carbon; m is an integer of 0 to 3; n is an integer of 1 to 3; Q represents a benzene ring optionally substituted by hydroxy, halogeno, lower alkenyl, lower alkoxy, lower alkyl, and amino; R 1 represents a phenyl, naphthyl, or 5-or 6-membered aromatic heterocyclic group optionally substituted by hydroxy, halogeno, lower alkenyl, lower alkoxy, phenoxy, phenyl, lower alkyl, and amino; R 2 represents lower alkyl, carbamoyl, phenyl, or a 5-or 6-membered aromatic heterocyclic group; R3 and R4 each represents hydrogen or lower alkyl; R5 represents hydrogen, lower alkyl, or benzyl; and R6 represents hydrogen, hydroxy, halogeno, lower alkenyl, lower alkoxy, phenoxy, phenyl, lower alkyl, or amino

One of the oldest and most widely used commercial enzyme inhibitors is aspirin, 21169-71-1, which selectively inhibits one of the enzymes involved in the synthesis of molecules that trigger inflammation. you can also check out more blogs about 21169-71-1

Reference£º
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.21169-71-1,Isoxazole-5-carboxylic acid,as a common compound, the synthetic route is as follows.

To a solution of the above compound (35 mg, 1.0 mmol) in DMF (1 mL), isoxazole-5-carboxylic acid (23 mg, 0.20 mmol), 1-ethyl-(3-dimethylaminopropyl)carbodimide hydrochloride (38 mg 0.20 mmol), 1-hydroxy-7-azabenzotriazole (13.6 mg, 0.10 mmol), and N,N-diisopropylethylamine were added until pH=9.5. The resulting solution was stirred at room temperature for 3 hours and then 0.3 mL of water was added. Purification was achieved by preparative HPLC on a delta-pack C18 column, 300 , pore size 15 muM with 0.05% HCl acid -aqueous acetonitrile solvent systems using various linear gradients to afford the HCl salt of the title compound as a white solid that gave a proton NMR spectrum consistent with theory and a mass ion (ES+) of 442.2 for M+H+: 1H NMR (500 MHz, DMSO-d6) delta 1.61 (d, J=6.7 Hz, 3H), 2.21 (s, 3H), 5.47 (d, 1H), 6.86 (br s, 1 H), 7.36 (d, J=1.9 Hz, 1H), 7.49 (d, J=7.8 Hz, 1H), 7.55 (t, J=8.6 Hz, 1H), 7.83 (d, J=6.4 Hz, 1H), 7.85 (t, J=7.57 Hz, 1H), 8.86 (d, J=1.9 Hz, 1H), 10.54 (br s, 1H),, 21169-71-1

21169-71-1 Isoxazole-5-carboxylic acid 2060599, aIsoxazoles compound, is more and more widely used in various fields.

Reference£º
Patent; Kuduk, Scott D.; Bock, Mark G.; Feng, Dong-Mei; Wai, Jenny Miu-Chun; US2004/29920; (2004); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

21169-71-1, Isoxazole-5-carboxylic acid is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: Compounds were synthesized in solution phase using Boc-protected amino acids on 100-200mg scale. Firstly, the amino acid (1.2-1.5equiv) was activated with HBTU (1.5equiv) and DIPEA (1.5equiv) as 0.2-0.5M solution in DMF for 10min. Then the solution was added to an amino group bearing C-terminal moiety (R1R2NH) and the mixture was stirred for a minimum of 1h at room temperature. The reaction mixture was diluted with EtOAc and washed with saturated NaHCO3 (2¡Á). The organic extracts were dried over MgSO4, filtered and evaporated in vacuo. The crude product was then treated with 20% TFA in DCM and stirred for 1-2h to remove the Boc group. TFA was removed by evaporating the reaction mixture under a stream of N2. The residue was dissolved in DCM and washed with saturated NaHCO3 (2¡Á). DCM phase was dried with MgSO4, filtered and evaporated in vacuo. Subsequent N-Boc-amino acids and amines were sequentially coupled under the same conditions. Each coupling reaction was monitored by ESMS, with most reactions going to completion overnight. All final compounds were purified on rpHPLC (97% by analytical HPLC) and fully characterized by NMR and HRMS (yields between 30% and 40%).

21169-71-1, 21169-71-1 Isoxazole-5-carboxylic acid 2060599, aIsoxazoles compound, is more and more widely used in various fields.

Reference£º
Article; Yau, Mei-Kwan; Liu, Ligong; Lim, Junxian; Lohman, Rink-Jan; Cotterell, Adam J.; Suen, Jacky Y.; Vesey, David A.; Reid, Robert C.; Fairlie, David P.; Bioorganic and Medicinal Chemistry Letters; vol. 26; 3; (2016); p. 986 – 991;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

21169-71-1, Isoxazole-5-carboxylic acid is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: Compounds were synthesized in solution phase using Boc-protected amino acids on 100-200mg scale. Firstly, the amino acid (1.2-1.5equiv) was activated with HBTU (1.5equiv) and DIPEA (1.5equiv) as 0.2-0.5M solution in DMF for 10min. Then the solution was added to an amino group bearing C-terminal moiety (R1R2NH) and the mixture was stirred for a minimum of 1h at room temperature. The reaction mixture was diluted with EtOAc and washed with saturated NaHCO3 (2¡Á). The organic extracts were dried over MgSO4, filtered and evaporated in vacuo. The crude product was then treated with 20% TFA in DCM and stirred for 1-2h to remove the Boc group. TFA was removed by evaporating the reaction mixture under a stream of N2. The residue was dissolved in DCM and washed with saturated NaHCO3 (2¡Á). DCM phase was dried with MgSO4, filtered and evaporated in vacuo. Subsequent N-Boc-amino acids and amines were sequentially coupled under the same conditions. Each coupling reaction was monitored by ESMS, with most reactions going to completion overnight. All final compounds were purified on rpHPLC (97% by analytical HPLC) and fully characterized by NMR and HRMS (yields between 30% and 40%).

21169-71-1, 21169-71-1 Isoxazole-5-carboxylic acid 2060599, aIsoxazoles compound, is more and more widely used in various fields.

Reference£º
Article; Yau, Mei-Kwan; Liu, Ligong; Lim, Junxian; Lohman, Rink-Jan; Cotterell, Adam J.; Suen, Jacky Y.; Vesey, David A.; Reid, Robert C.; Fairlie, David P.; Bioorganic and Medicinal Chemistry Letters; vol. 26; 3; (2016); p. 986 – 991;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.21169-71-1,Isoxazole-5-carboxylic acid,as a common compound, the synthetic route is as follows.

21169-71-1, A solution of 5-isoxazolecarboxylic acid (500 mg, 4.42 mmol, commercially available from e.g. Sigma-Aldrich, Maybridge or Apollo) in dry dichloromethane (DCM) (14.700 ml) was stirred at room temperature under an atmosphere of argon. EDC (1017 mg, 5.31 mmol) and HOBt (339 mg, 2.21 1 mmol) were added to the solution and stirring was continued at room temperature for 1/2 hour. After this time, 1 ,1-dimethylethyl hydrazinecarboxylate (701 mg, 5.31 mmol) was added to the reaction mixture and stirring was continued for a further 18 hours at room temperature (overnight). The solution was diluted with DCM (approx 30 ml) and washed with water (2 x 20 ml). The organics were dried over MgSO4, filtered and concentrated under reduced pressure to give a colourless oil. The oil was chromatographed [Sitheta2, EtOAc/Hexane 0-100%] to give a colourless, thick oil in 321 mg. The oil was used directly in the next step. LCMS [M-H] 226.22 and [M+H- BOC]+ 128.07 (at) 0.60 min (2 min run).

21169-71-1 Isoxazole-5-carboxylic acid 2060599, aIsoxazoles compound, is more and more widely used in various fields.

Reference£º
Patent; GLAXO GROUP LIMITED; DEAN, David Kenneth; MUNOZ-MURIEDAS, Jorge; SIME, Mairi; STEADMAN, Jon Graham Anthony; THEWLIS, Rachel Elizabeth Anne; TRANI, Giancarlo; WALTER, Daryl Simon; WO2010/125102; (2010); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

21169-71-1, Isoxazole-5-carboxylic acid is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

a N-Methoxy-N-methyl-5-isoxazolecarboxamide A solution of isoxazole 5-carboxylic acid (2.81 g), N-methoxy-N-methylamine hydrochloride (2.49 g), EDCI (4.96 g), dimethylaminopyridine (3.15 g) and 4-methylmorpholine (2.8 ml) in dichloromethane (20 ml) was stirred for 18 h. 2M Hydrochloric acid was added and the mixture was extracted with dichloromethane (three times). The organic layers were washed with aqueous sodium hydrogen carbonate and then brine, combined, dried (magnesium sulphate), evaporated and purified by chromatography on silica eluding with petrol-ether to give the sub-title compound as a colourless oil (2.94 g, 76%). 1H NMR 300 MHz (CDCl3) 8.35 (1H, d), 6.89 (1H, d), 3.83 (3H, s), 3.39 (3H, s)., 21169-71-1

21169-71-1 Isoxazole-5-carboxylic acid 2060599, aIsoxazoles compound, is more and more widely used in various fields.

Reference£º
Patent; Cheshire, David; Connolly, Stephen; Cox, David; Hamley, Peter; Mete, Antonio; Pimm, Austen; US2003/158185; (2003); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.21169-71-1,Isoxazole-5-carboxylic acid,as a common compound, the synthetic route is as follows.

General procedure: Compounds were synthesized in solution phase using Boc-protected amino acids on 100-200mg scale. Firstly, the amino acid (1.2-1.5equiv) was activated with HBTU (1.5equiv) and DIPEA (1.5equiv) as 0.2-0.5M solution in DMF for 10min. Then the solution was added to an amino group bearing C-terminal moiety (R1R2NH) and the mixture was stirred for a minimum of 1h at room temperature. The reaction mixture was diluted with EtOAc and washed with saturated NaHCO3 (2¡Á). The organic extracts were dried over MgSO4, filtered and evaporated in vacuo. The crude product was then treated with 20% TFA in DCM and stirred for 1-2h to remove the Boc group. TFA was removed by evaporating the reaction mixture under a stream of N2. The residue was dissolved in DCM and washed with saturated NaHCO3 (2¡Á). DCM phase was dried with MgSO4, filtered and evaporated in vacuo. Subsequent N-Boc-amino acids and amines were sequentially coupled under the same conditions. Each coupling reaction was monitored by ESMS, with most reactions going to completion overnight. All final compounds were purified on rpHPLC (97% by analytical HPLC) and fully characterized by NMR and HRMS (yields between 30% and 40%).

21169-71-1, The synthetic route of 21169-71-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Yau, Mei-Kwan; Liu, Ligong; Lim, Junxian; Lohman, Rink-Jan; Cotterell, Adam J.; Suen, Jacky Y.; Vesey, David A.; Reid, Robert C.; Fairlie, David P.; Bioorganic and Medicinal Chemistry Letters; vol. 26; 3; (2016); p. 986 – 991;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem